-
’Day one’ launch in major European markets immediately on patent
expiry
-
Move adds Germany, UK, and Italy and six other European countries
to markets where Teva has generic available
JERUSALEM--(BUSINESS WIRE)--Jun. 24, 2013--
Teva Pharmaceutical Industries Ltd (NYSE:TEVA) announced today that it
had launched a generic version of Viagra® (sildenafil) immediately on
patent expiry in Germany, the United Kingdom, Italy, the Netherlands,
Switzerland, Ireland, Austria, Belgium and Denmark. The company had
already launched the product in Spain, Canada and certain other
countries.
Dipankar Bhattacharjee, President and CEO Europe Generics, welcomed the
launch: “Teva has a proud track record of bringing high-quality generics
to the market on day one of patent expiry, and we have been able to
launch sildenafil immediately on patent expiry in all the major markets
of Europe. The launch today of sildenafil will bring choice to the
pharmacy to help them serve the patient, and to help ensure that
high-quality healthcare in Europe is affordable.”
Teva is supplying the market via its existing wholesaler and pharmacy
channels and will not, in line with European legislation, offer the
product directly to consumers.
About sildenafil and erectile dysfunction (ED)
Sildenafil is used to treat erectile dysfunction in adult men. In the
natural setting, i.e. with sexual stimulation, it restores impaired
erectile function by increasing blood flow to the penis. Erectile
dysfunction or ED is the inability to achieve or maintain a penile
erection sufficient for satisfactory sexual performance. Problems with
erections may be related to a wide variety of factors. In approximately
half of men ED is age-related problem, but very often it can be
associated with chronic illness like atherosclerosis and diabetes, or
psychiatric illness like depression. It may also occur in men with other
chronic illnesses like chronic heart failure, hepatic failure, multiple
sclerosis, Alzheimer disease, chronic obstructive pulmonary disease. Men
with endocrine disorders, such as hypogonadism, hyperprolactinaemia, and
hypo- or hyper-thyroidism are also at greater risk. Problems with
erections may also stem from medications, drinking too much alcohol, or
tiredness.
About Teva
Teva Pharmaceutical Industries Ltd. (NYSE: TEVA) is a leading global
pharmaceutical company, committed to increasing access to high-quality
healthcare by developing, producing and marketing affordable generic
drugs as well as innovative and specialty pharmaceuticals and active
pharmaceutical ingredients. Headquartered in Israel, Teva is the world's
leading generic drug maker, with a global product portfolio of more than
1,000 molecules and a direct presence in about 60 countries. Teva's
branded businesses focus on CNS, oncology, pain, respiratory and women's
health therapeutic areas as well as biologics. Teva currently employs
approximately 46,000 people around the world and reached $20.3 billion
in net revenues in 2012.
Teva's Safe Harbor Statement under the U. S. Private Securities
Litigation Reform Act of 1995:
This release contains forward-looking statements, which express the
current beliefs and expectations of management. Such statements are
based on management’s current beliefs and expectations and involve a
number of known and unknown risks and uncertainties that could cause our
future results, performance or achievements to differ significantly from
the results, performance or achievements expressed or implied by such
forward-looking statements. Important factors that could cause or
contribute to such differences include risks relating to: our ability to
develop and commercialize additional pharmaceutical products,
competition for our innovative products, especially Copaxone® (including
competition from innovative orally-administered alternatives, as well as
from potential purported generic equivalents), competition for our
generic products (including from other pharmaceutical companies and as a
result of increased governmental pricing pressures), competition for our
specialty pharmaceutical businesses, our ability to achieve expected
results through our innovative R&D efforts, the effectiveness of our
patents and other protections for innovative products, decreasing
opportunities to obtain U.S. market exclusivity for significant new
generic products, our ability to identify, consummate and successfully
integrate acquisitions, the effects of increased leverage as a result of
recent acquisitions, the extent to which any manufacturing or quality
control problems damage our reputation for high quality production and
require costly remediation, our potential exposure to product liability
claims to the extent not covered by insurance, increased government
scrutiny in both the U.S. and Europe of our agreements with brand
companies, potential liability for sales of generic products prior to a
final resolution of outstanding patent litigation, our exposure to
currency fluctuations and restrictions as well as credit risks, the
effects of reforms in healthcare regulation and pharmaceutical pricing
and reimbursement, any failures to comply with complex Medicare and
Medicaid reporting and payment obligations, governmental investigations
into sales and marketing practices (particularly for our specialty
pharmaceutical products), uncertainties surrounding the legislative and
regulatory pathways for the registration and approval of
biotechnology-based products, adverse effects of political or economical
instability, corruption, major hostilities or acts of terrorism on our
significant worldwide operations, interruptions in our supply chain or
problems with our information technology systems that adversely affect
our complex manufacturing processes, any failure to retain key personnel
or to attract additional executive and managerial talent, the impact of
continuing consolidation of our distributors and customers, variations
in patent laws that may adversely affect our ability to manufacture our
products in the most efficient manner, potentially significant
impairments of intangible assets and goodwill, potential increases in
tax liabilities, the termination or expiration of governmental programs
or tax benefits, environmental risks and other factors that are
discussed in our Annual Report on Form 20-F for the year ended December
31, 2012 and in our other filings with the U.S. Securities and Exchange
Commission. Forward-looking statements speak only as of the date on
which they are made and the Company undertakes no obligation to update
or revise any forward-looking statement, whether as a result of new
information, future events or otherwise.
Source: Teva Pharmaceutical Industries Ltd.
IR Contacts:
Kevin C. Mannix, 215-591-8912
United States
or
Ran
Meir, 215-591-3033
United States
or
Tomer Amitai,
972 (3) 926-7656
Israel
or
PR Contacts:
Iris
Beck Codner, 972 (3) 926-7687
Israel
or
Denise
Bradley, 215-591-8974
United States
or
Paul
Williams, 31 346 290 312
Europe